Greater Manchester has the unique ability to deliver innovation into clinical practice at pace and scale, thanks to its £6bn devolved health and social care system, unrivalled digital assets and ambitions, exceptional academic and research capability and thriving industry partnerships.
Under the partnership agreement with the ABPI, Greater Manchester already has four significant pharma innovation projects in progress covering COPD, mental health, Hepatitis C and virtual biologics. There are now plans to mobilise a further six projects by the end of the year, providing opportunity for new proposals to be developed.
A Memorandum of Understanding between Health Innovation Manchester, the Greater Manchester Health and Social Care Partnership (GMHSCP) and the Association of British HealthTech Industries (ABHI) has been approved and is set to be signed soon.
The MoU articulates how Greater Manchester will work with the health technology sector through the creation of a strategic partnership with the Association of British HealthTech Industries. All Signatories share the same ambition ‘to make Greater Manchester a world-leading location in the adoption of clinically- and cost-effective health and care innovations; and an important global site for real world evidence (RWE) generation and evaluation’.
Not only will this MoU lead to improved outcomes and patient experience, it will also ensure value for money for the NHS and local government as well as attract inward investment into the city-region – contributing towards economic growth. To read the GMHSCP report and the MoU in full click here
ABHI is the UK’s leading health technology trade association. With over 275 members, ABHI supports the health technology community to provide products and services that help people live healthier lives. Their work is focused on showing the value of HealthTech and encouraging a healthy environment for economic growth. We help companies understand HealthTech regulation and our work is underpinned by our Code of Business Practice, which all Members adhere to.
Last year, Health Innovation Manchester – which brings together industry and academia with health and social care to accelerate innovation across Greater Manchester – commenced the development of an Early Dementia Diagnostic Framework. Working with academia; the healthcare system; life sciences industry partners – including Janssen, a pharmaceutical company of Johnson & Johnson – commissioners; and providers within the region, we’re considering ways we can prevent the onset of dementia, in future.
A key part of this was establishing a partnership with the Dementia Industry Group (DIG) – a life sciences industry collaborative group, of which Janssen is a core member, along with other pharmaceutical companies. They support the UK in leading the field of dementia treatment and research. Together, we set out principles for collaboration and the following framework workstreams, all of which will tackle the issue of dementia like never before:
- Public involvement and engagement – to increase detection of symptomatic people
- Risk profiling and biomarkers – to better identify the specific needs of symptomatic people
- Data access and platform development – to enable effective screening and recording
- Future care pathway and tracking development – to outline the process and to better support those affected
- Ethics, regulatory aspects and health economics – to address the ethical and regulatory aspects of a detection framework
- Funding and intervention – to address the affordability aspect for new interventions in dementia
Our overriding vision is to improve outcomes in dementia by ensuring optimal access and uptake of innovative technologies and treatments for eligible patients; as well as ensuring the healthcare system is geared up to provide the best support for people living with dementia.
The six workstreams outlined, each have experts from the collaborating parties of the partnership working to a December 2018 deadline to produce a set of practical recommendations for making an early dementia diagnostic framework a reality. With a feedback event being planned for early next year, these exciting times are really gathering pace.
The early warning signs of dementia have never before been systematically documented for analysis, and having a framework in place to fully support those affected will be key to delivering more personalised care.
The ultimate aim of the framework is to act as a functioning early diagnostic marker in clinical practice, so when disease-modifying treatments become available, people who may benefit can be rapidly identified and treated in time.
If successful, the extensive dementia treatment framework being devised in Manchester has the potential to be replicated across the partnership network and rolled out globally – positively impacting the millions of people affected by dementia, and their loved ones.
Established by the European Union ERDF funds help local areas stimulate their economic development by investing in projects which will support innovation, businesses, create jobs and local community regenerations. The ‘Building capacity and capability in health and life science businesses in Cheshire & Warrington’ project is part-funded by the European Regional Development Fund.